30 years of historical data (1995–2024) · Healthcare · Drug Manufacturers - General
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Eli Lilly and Company trades at 89.9x earnings, 52% above its 5-year average of 59.1x, sitting at the 96th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a premium of 279%. On a free-cash-flow basis, the stock trades at 2273.1x P/FCF, 393% above the 5-year average of 461.3x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $941.7B | $697.9B | $526.5B | $347.6B | $263.4B | $161.5B | $125.8B | $119.6B | $88.9B | $81.0B | $93.1B |
| Enterprise Value | $972.1B | $728.3B | $548.9B | $361.8B | $276.5B | $174.4B | $139.3B | $122.6B | $96.0B | $86.7B | $97.4B |
| P/E Ratio → | 89.85 | 65.93 | 100.50 | 55.68 | 47.22 | 26.10 | 15.12 | 36.97 | — | 29.54 | 38.65 |
| P/S Ratio | 20.91 | 15.49 | 15.43 | 12.18 | 9.30 | 6.58 | 5.64 | 5.57 | 4.45 | 3.82 | 4.67 |
| P/B Ratio | 66.65 | 48.90 | 48.47 | 32.26 | 28.77 | 27.73 | 46.63 | 10.96 | 7.62 | 5.75 | 6.38 |
| P/FCF | 2273.08 | 1684.61 | — | 75.56 | 48.89 | 36.13 | 36.13 | 47.73 | 25.74 | 21.54 | 69.58 |
| P/OCF | 106.80 | 79.15 | 124.18 | 45.82 | 35.76 | 24.85 | 26.02 | 21.65 | 15.82 | 16.69 | 31.41 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Eli Lilly and Company's enterprise value stands at 50.5x EBITDA, 51% above its 5-year average of 33.5x. The Healthcare sector median is 13.8x, placing the stock at a 264% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 16.17 | 16.09 | 12.68 | 9.76 | 7.11 | 6.24 | 5.70 | 4.80 | 4.09 | 4.88 |
| EV / EBITDA | 50.45 | 37.80 | 44.58 | 35.55 | 29.16 | 20.44 | 19.26 | 16.06 | 16.50 | 16.15 | 19.41 |
| EV / EBIT | 55.54 | 54.11 | 77.97 | 50.68 | 42.57 | 22.99 | 24.59 | 31.25 | 37.93 | 24.36 | 33.02 |
| EV / FCF | — | 1757.93 | — | 78.64 | 51.32 | 39.02 | 40.00 | 48.91 | 27.80 | 23.06 | 72.80 |
Margins and return-on-capital ratios measuring operating efficiency
Eli Lilly and Company earns an operating margin of 38.9%. Operating margins have expanded from 30.3% to 38.9% over the past 3 years, signaling improving operational efficiency. Return on equity of 84.3% is exceptionally high. ROIC of 33.7% represents excellent returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.3% | 81.3% | 79.2% | 76.8% | 74.2% | 77.7% | 78.8% | 78.2% | 77.7% | 73.1% | 74.8% |
| Operating Margin | 38.9% | 38.9% | 31.6% | 30.3% | 28.0% | 29.4% | 26.9% | 28.0% | 21.3% | 18.2% | 18.0% |
| Net Profit Margin | 23.5% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% | 15.0% | -1.0% | 12.9% | 12.1% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 84.3% | 84.3% | 48.4% | 62.7% | 74.5% | 145.3% | 122.3% | 28.6% | -1.6% | 19.1% | 16.1% |
| ROA | 14.8% | 14.8% | 9.2% | 12.7% | 11.7% | 14.4% | 20.0% | 7.3% | -0.5% | 7.4% | 6.7% |
| ROIC | 33.7% | 33.7% | 27.8% | 27.5% | 29.0% | 31.0% | 29.9% | 27.7% | 16.5% | 15.0% | 14.0% |
| ROCE | 40.2% | 40.2% | 31.2% | 26.2% | 23.4% | 23.4% | 20.2% | 19.3% | 14.6% | 14.0% | 13.7% |
Solvency and debt-coverage ratios — lower is generally safer
Eli Lilly and Company carries a Debt/EBITDA ratio of 1.7x, which is manageable (44% below the sector average of 3.1x). Net debt stands at $30.4B ($33.6B total debt minus $3.3B cash). Interest coverage of 22.4x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.36 | 2.36 | 2.32 | 1.51 | 1.84 | 2.85 | 5.86 | 0.94 | 1.17 | 0.73 | 0.55 |
| Debt / EBITDA | 1.75 | 1.75 | 2.05 | 1.60 | 1.78 | 1.94 | 2.19 | 1.35 | 2.35 | 1.92 | 1.59 |
| Net Debt / Equity | — | 2.13 | 2.06 | 1.32 | 1.43 | 2.22 | 4.99 | 0.27 | 0.61 | 0.41 | 0.30 |
| Net Debt / EBITDA | 1.58 | 1.58 | 1.82 | 1.39 | 1.38 | 1.52 | 1.86 | 0.39 | 1.22 | 1.07 | 0.86 |
| Debt / FCF | — | 73.32 | — | 3.08 | 2.43 | 2.89 | 3.87 | 1.19 | 2.06 | 1.52 | 3.22 |
| Interest Coverage | 22.42 | 22.42 | 22.20 | 26.10 | 23.35 | 20.05 | 14.98 | 24.85 | 18.89 | 20.90 | 22.28 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.15x means Eli Lilly and Company can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 1.05x to 1.15x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.15 | 1.15 | 0.94 | 1.05 | 1.23 | 1.40 | 1.16 | 1.73 | 1.32 | 1.37 | 1.53 |
| Quick Ratio | 0.89 | 0.89 | 0.73 | 0.80 | 0.97 | 1.08 | 0.89 | 1.47 | 1.01 | 1.05 | 1.11 |
| Cash Ratio | 0.12 | 0.12 | 0.11 | 0.13 | 0.26 | 0.29 | 0.21 | 0.62 | 0.55 | 0.55 | 0.54 |
| Asset Turnover | — | 0.57 | 0.53 | 0.58 | 0.58 | 0.53 | 0.57 | 0.49 | 0.44 | 0.55 | 0.56 |
| Inventory Turnover | 1.11 | 1.11 | 1.23 | 1.54 | 1.88 | 1.38 | 1.48 | 1.51 | 1.00 | 1.60 | 1.46 |
| Days Sales Outstanding | — | 107.58 | 121.25 | 109.45 | 104.75 | 103.06 | 90.62 | 98.10 | 96.16 | 81.98 | 74.46 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Eli Lilly and Company returns 0.8% to shareholders annually — split between a 0.5% dividend yield and 0.3% buyback yield. A payout ratio of 44.2% is moderate and appears sustainable, balancing shareholder returns with reinvestment capacity. The earnings yield of 1.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.5% | 0.7% | 0.8% | 1.0% | 1.2% | 1.7% | 1.9% | 1.9% | 2.5% | 2.7% | 2.3% |
| Payout Ratio | 44.2% | 44.2% | 77.7% | 56.6% | 55.3% | 43.4% | 29.0% | 71.5% | — | 78.8% | 88.3% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.1% | 1.5% | 1.0% | 1.8% | 2.1% | 3.8% | 6.6% | 2.7% | — | 3.4% | 2.6% |
| FCF Yield | 0.0% | 0.1% | — | 1.3% | 2.0% | 2.8% | 2.8% | 2.1% | 3.9% | 4.6% | 1.4% |
| Buyback Yield | 0.3% | 0.4% | 0.1% | 0.4% | 0.5% | 0.3% | 3.5% | 3.5% | 0.3% | 0.7% | 0.8% |
| Total Shareholder Yield | 0.8% | 1.0% | 0.9% | 1.4% | 1.6% | 2.0% | 5.4% | 5.4% | 2.8% | 3.4% | 3.1% |
| Shares Outstanding | — | $904M | $903M | $950M | $954M | $957M | $958M | $1.0B | $1.1B | $1.1B | $1.1B |
Compare LLY with 3 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| LLYYou | $942B | 89.9 | 50.5 | 2273.1 | 81.3% | 38.9% | 84.3% | 33.7% | 1.7 |
| JNJ | $599B | 42.9 | 20.7 | 30.2 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
| AZN | $323B | 63.7 | 17.8 | 27.5 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
| BMY | $127B | -14.1 | 8.7 | 9.1 | 56.8% | 20.0% | -39.0% | 12.4% | 2.7 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how LLY stacks up against sector leader Johnson & Johnson.
Start ComparisonEli Lilly and Company's current P/E ratio is 89.9x. The historical average is 31.2x. This places it at the 96th percentile of its historical range.
Eli Lilly and Company's current EV/EBITDA is 50.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 18.5x.
Eli Lilly and Company's return on equity (ROE) is 84.3%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 39.8%.
Based on historical data, Eli Lilly and Company is trading at a P/E of 89.9x. This is at the 96th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Eli Lilly and Company's current dividend yield is 0.49% with a payout ratio of 44.2%.
Eli Lilly and Company has 81.3% gross margin and 38.9% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Eli Lilly and Company's Debt/EBITDA ratio is 1.7x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.